Frequently Asked Questions
The market is segmented based on , By Product and Services (Assay Kits and Reagents, Software & Services), Technology (Polymerase Chain Reaction, Molecular Diagnostics, FISH, CISH, Immunohistochemistry, Real-time PCR, Next-Generation Sequencing, Gene Sequencing, In Situ Hybridization), Indication (Oncology, Neurology, Infectious Diseases), Application (Colorectal Cancer, Breast Cancer, Lung Cancer, Melanoma, Urology, Gastric Cancer), End Users (Pharmaceutical and Biopharmaceutical Companies, Reference Laboratories), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028
.
The Global Companion Diagnostics Market size was valued at USD 0.00 USD Million in 2021.
The Global Companion Diagnostics Market is projected to grow at a CAGR of 13.85% during the forecast period of 2022 to 2028.
The major players operating in the market include F. Hoffmann-La Roche , Qiagen, Abbott, Almac Group, Agilent Technologies , Clinical Lab Products, Myriad Genetics , Leica Biosystems Nussloch GmbH, Resonance Health, ARUP Laboratories, Life Technologies, Sysmex Corporation, Thermo Fisher Scientific , Illumina , Hologic , Abnova Corporation, bioMérieux SA, Siemens Healthcare Private Limited,.
